Find Clinical Trials

Inclusion Criteria COHORT 1 and COHORT 2 are no longer enrolling. PHASE I PRE-REGISTRATION, ALL: * Willing to provide tissue specimens per protocol * NOTE: includes fresh tissue specimen at pre-registration for complete exome and transcriptome sequencing. Patients who had tumor sequencing under certain Mayo Institutional Review Board (IRB) protocols and neoantigen has been identified or REAL Neo vaccine produced are allowed to proceed to pre-registration and/or registration. * Measurable disease as defined by RECIST (version 1.1) criteria or non-measurable disease * NOTE: Tumor lesions in previously irradiated area are not considered measurable disease * Patients with actionable genomic abnormality including, but not limited to EGFR, ALK, MET, ROS-1, RET, NTRK, KRAS or BRAF must have received and progressed on at least one line of prior FDA-approved targeted therapy * Provide written informed consent * Willing to return to enrolling institution for follow-up * Willing to provide blood specimens for research * Negative pregnancy test =\< 7 days prior to pre-registration for persons of childbearing potential. If urine test cannot be confirmed negative, serum pregnancy test will be required. * Willing to employ highly effective method of contraception from pre-registration through 6 months after final vaccine cycle * Willing to receive tetanus vaccination if subject has not had one =\< 1 year prior to pre-registration * Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1 * Anticipated life expectancy \> 6 months * Recovered from all toxicities associated with prior treatment to acceptable baseline status (see specified inclusion limits for laboratory toxicity) or National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 Grade 0 or 1, except for toxicities not considered safety risk per treating investigator (e.g., alopecia or vitiligo). * The following lab values obtained =\< 28 days prior to pre-registration: * Hemoglobin \>= 9.0 g/dL (Must be \>= 7 days after most recent transfusion) * Absolute neutrophil count (ANC) \>= 1500/mm\^3 or \>= 1.5 X 10\^9/L * Platelet count \>= 100,000/mm\^3 or \>= 100 X 10\^9/L (Must be \>=7 days after most recent transfusion) * Total bilirubin =\< 1.5 x upper limit of normal (ULN) * Aspartate transaminase (AST) and alanine transaminase (ALT) =\< 3 x ULN or =\< 5 x ULN with liver metastases * Creatinine =\< 1.5 x ULN OR calculated creatinine clearance must be \>= 50 ml/min using Cockcroft-Gault formula * International normalized ratio (INR) or prothrombin time (PT) and activated partial thromboplastin time (aPTT) =\< 1.5 x ULN unless patient is receiving anticoagulant therapy in which case PT or PTT must be within target range of therapy PHASE I REGISTRATION, ALL: * Successful sequencing and production of REAL-Neo vaccine * Measurable disease as defined by RECIST (version 1.1) criteria or non-measurable disease * NOTE: Tumor lesions in previously irradiated area are not considered measurable disease * ECOG PS 0 or 1 * Anticipated life expectancy \> 6 months * The following lab values obtained =\< 14 days prior to registration: * Hemoglobin \>= 9.0 g/dl * ANC \>= 1500/mm\^3 * Platelet count \>= 100,000/mm\^3 * Total bilirubin =\< 1.5 x ULN * ALT and AST =\< 3 x ULN (=\< 5 x ULN with liver involvement) * PT/INR and aPTT =\< 1.5 x ULN unless patient is receiving anticoagulant therapy in which case INR or aPTT must be within target range of therapy * Calculated creatinine clearance \>= 50 ml/min using Cockcroft-Gault formula * Provide written informed consent * Willing to provide blood and tissue specimens for research * Willing to return to enrolling institution for follow-up * Patients with actionable genomic abnormality including, but not limited to EGFR, ALK, MET, ROS-1, RET, NTRK, KRAS or BRAF must have also received and progressed on at least one line of prior FDA-approved targeted therapy * Negative pregnancy test =\< 14 days prior to registration for persons of childbearing potential only * NOTE: If urine test cannot be confirmed negative, serum pregnancy test will be required * Willing to employ highly effective method of contraception from pre-registration through 6 months after final vaccine cycle * Willing to receive tetanus vaccination if subject has not had one =\< 1 year prior to pre-registration * Recovered from all toxicities associated with prior treatment to acceptable baseline status (for laboratory toxicity see specified limits for inclusion) or NCI CTCAE version 5.0 Grade of 0 or 1, except for toxicities not considered safety risk per treating investigator (e.g., alopecia or vitiligo) PHASE II PRE-SCREENING COHORT 3 ONLY: * ECOG PS 0 or 1 * Histological confirmation of adenocarcinoma of the breast with estrogen receptor (ER) \< 10%, progesterone receptor (PR) \< 10%, and HER2 negative based on current American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guideline * Stage I-III based on 7th edition of TNM staging system from American Joint Committee on Cancer (AJCC) * Evidence of residual disease \>= 1 cm after neoadjuvant pembrolizumab-based chemotherapy on imaging for patients who have not had surgery * Willing to proceed with surgery and provide tissue and blood specimens for patients who have not had surgery * Provide written informed consent * Willing to return to enrolling institution for follow-up PHASE II PRE-SCREENING COHORT 4 ONLY: * ECOG PS 0 or 1 * Histological confirmation of lung NSCLC * No actionable EGFR mutations and ALK fusions * Stage II or stage III based on AJCC 8th * Tumor \>= 2 cm on pre-surgery evaluation imaging (residual disease \>= 2 cm after neoadjuvant therapy on pre-surgery evaluation imaging in patient who receives neoadjuvant therapy) for patients who have not had surgery. Patients with or without neoadjuvant chemotherapy or immunotherapy are allowed * Provide written informed consent * Willing to proceed with surgery and provide tissue and blood specimens for patients who have not had surgery * Willing to return to enrolling institution for follow-up PHASE II PRE-REGISTRATION COHORT 3 (TNBC) ONLY: * Histologically confirmed residual cancer burden 2 and 3 in surgical specimens PHASE II PRE-REGISTRATION COHORT 4 (NSCLC) ONLY: * Tumor without complete pathologic response is confirmed in pathology * Willing to proceed with surgery and provide tissue specimens for complete exome and transcriptome sequencing * NOTE: Patients who had sequencing under certain Mayo IRB protocols and neoantigens identified or REAL Neo vaccine produced are allowed to proceed to pre-registration and/or registration * Negative pregnancy test ≤7 days prior to pre-registration for persons of childbearing potential only. If urine test cannot be confirmed negative, serum pregnancy test will be required. * Willing to employ highly effective method of contraception from pre-registration through 6 months after final vaccine cycle * ECOG PS of 0 or 1 * Anticipated life expectancy \> 6 months PHASE II REGISTRATION: * Successful sequencing and production of REAL-Neo vaccine * Patients will receive \>= 2 additional cycles of maintenance pembrolizumab * ECOG PS 0 or 1 * Anticipated life expectancy \> 6 months * The following lab values obtained =\< 14 days prior to registration: * Hemoglobin \>= 9.0 g/dl * ANC \>= 1500/mm\^3 * Platelet count \>= 100,000/mm\^3 * Total bilirubin =\< 1.5 x ULN * ALT and AST =\< 3 x ULN (=\< 5 x ULN with liver involvement) * PT/INR and aPTT =\< 1.5 x ULN unless patient is receiving anticoagulant therapy in which case INR or aPTT must be within target range of therapy * Calculated creatinine clearance \>= 50 ml/min using Cockcroft-Gault formula * Provide written informed consent * Willing to provide blood specimens for research * Willing to return to enrolling institution for follow-up * Negative pregnancy test =\< 1

Inclusion Criteria: * major depression, single episode or recurrent; * ability to read and write English; * Mini-Mental State Examination \>25. Exclusion Criteria: * lifetime alcohol/drug dependence * conditions associated with brain abnormalities such hydrocephalus, benign and cancerous brain tumors, epilepsy, Parkinson's disease, Huntington's chorea, dementia, demyelinating diseases, etc. * untreated endocrine disorder other than diabetes mellitus * established clinical diagnosis of dementia * other primary psychiatric disorders, e.g., panic disorder, social phobia, obsessive- compulsive disorder, schizoaffective disorder, schizophrenia, bipolar disorder

Inclusion Criteria: 1. Women aged≥18 years and ≤75 years meeting one of the following conditions; 1. Those previously receiving ovariectomy, or aged ≥60 years 2. Those aged \< 60 years who have had 12 consecutive months of amenorrhoea without any pathological or physical causes, and have postmenopausal E2 and follicle stimulating hormone (FSH) levels 3. Premenopausal or perimenopausal women who are willing to receive LHRH agonist treatment during the study period 2. Women who have breast cancer histopathologically confirmed by positive estrogen receptor (ER; \>10%), positive progesterone receptor (PR; \>1%), and positive human epidermal growth factor receptor 2 (HER2) according to the 2018 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) human epidermal growth factor receptor 2 (HER2) guideline. ER, PR and HER2 will be assessed by immunohistochemistry (IHC) on harvested tissue. ER, PR and HER2 will be considered positive if the IHC result is positive (score 3+), or the IHC result is positive (2+) and in situ hybridization (ISH) amplification rate (≥2.0); 3. Women having stage II-III breast cancer diagnosed based on AJCC cancer staging system (8th edition) who will be admitted because of breast cancer for the first time; 4. Karnofsky Performance Status (KPS) Scale score ≥70; 5. The functional level of organs must meet the following requirements: a) Bone marrow function i) Absolute neutrophil count（ANC）≥1.5×109/L (no use of growth factor within 14 days) ii) Platelet count（PLT）≥100×109/L (no corrective treatment within 7 days) iii) Hemoglobin level（Hb）≥100 g/L (no corrective treatment within 7 days) b) Liver and kidney function i) Total bilirubin（TBIL）≤1.5 upper limit of normal value (ULN) ii) Alanine transaminase (ALT) and aspartate transaminase (AST) ≤3×ULN iii) Blood urea nitrogen (BUN) and creatinine ≤1.5×ULN and creatinine clearance≥50 mL/min (Cockcroft-Gault formula); c) Color Doppler echocardiography: Left ventricular ejection fraction ≥50% d) 12-lead electrocardiography: QTc interval ≤480 ms 6. Women who can undergo a biopsy; 7. Volunteers to participate in the study, provision of signed informed consent, good compliance and willingness to cooperate with follow-ups. Exclusion Criteria: 1. Women who have received any form of anti-tumor treatment - (chemotherapy, radiotherapy, molecular targeted therapy, or endocrine therapy); 2. Those who have received other anti-tumor drug treatments concurrently; 3. Those who have bilateral breast cancer, inflammatory breast cancer or occult breast cancer; 4. Those who have stage IV breast cancer; 5. Those who have breast cancer not histopathologically confirmed; 6. Those who have other malignant tumors (with the exception of healed cervical carcinoma in situ) occurring in the past 5 years; 7. Those who have severe dysfunction of the heart, liver, kidney, and other major organs; 8. There are multiple factors that affect drug administration and absorption, such as inability to swallow, chronic diarrhea, and intestinal obstruction; 9. Those who have participated in other clinical drug trials in the past 4 weeks; 10. Those who are known to have a history of allergy to the component of study drugs; those who have a history of immunodeficiency, including positive detection of human immunodeficiency virus, hepatitis C virus, active hepatitis B or other acquired, congenital immunodeficiency diseases, or organ transplantation; 11. Those who had suffered from any heart disease, including arrhythmia which requires drug treatment or is of clinical significance; myocardial infarction; heart failure; and any other heart disease judged by the investigator as unsuitable for this trial; 12. Pregnant and lactating women; fertile women who provide positive results of baseline pregnancy test; women of childbearing age who are unwilling to take effective contraceptive measures during the whole study period; 13. If the accompanying diseases (including, but not limited to, severe hypertension, severe diabetes, and active infection, which cannot be controlled by drugs) that would be a potential hazard to participant's health, or affect the completion of the study as per investigator's judgement; 14. A clear history of neurological or psychiatric disorders, including epilepsy or dementia. Upon the suggestion of the investigators for other reasons

Inclusion Criteria: * Woman aged 18-85 years who comes to the Cancer Risk Management Platform (CRMP) for a breast cancer risk assessment * A woman who has signed an informed consent form * Woman who is a beneficiary or entitled person of a social security plan Exclusion Criteria: * Woman diagnosed with breast cancer * Woman under legal protection (guardianship, curatorship) * Woman under AME

Inclusion Criteria: * Any participant who is receiving study treatment and deriving clinical benefit as determined by the investigator in a Pfizer-sponsored palbociclib Parent Study * Participants must agree to follow the reproductive criteria * Participants who are willing and able to comply with all scheduled visits, treatment plans, and other study procedures * Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent document and protocol Exclusion Criteria: * Any medical reason that, in the opinion of the investigator or sponsor, precludes the participant from inclusion in the study

Inclusion Criteria: * Express consent to participate in the study * Only for case group: primary open angle glaucoma (defined as the presence of visual field damage attributed to glaucomatous optic neuropathy) in both eyes * Only for control group: Absence optic nerve pathology (including primary open angle glaucoma) Exclusion Criteria: * Pregnant or breastfeeding woman * Sleep apnea * Renal insufficiency * Parkinson's disease * Alzheimer's disease * Antiphospholipid syndrome * Cancer for which treatment ended less than 2 years ago * Stroke less than 1 year ago * Myocardial infarction less than 1 year ago

Inclusion Criteria: * primary, solitary/multifocal, unilateral cTis-T2 breast cancer eligible for BCS * DCIS, ductal, lobular and other subtypes of invasive breast cancer (excluding LCIS and ADH) * ASA 1-2 and life expectancy more than 3 years * mammogram done with a device showing compression thickness * no previous breast surgery (bilateral reduction mammoplasty or mastopexy accepted) Exclusion Criteria: * metastatic breast cancer * previous ipsi- or contralateral breast cancer * bilateral breast cancer * hereditary breast cancer * contralateral symmetrization procedure in conjunction with the cancer surgery * contraindication for radiotherapy * neoadjuvant treatment * pregnancy or breastfeeding * inability to provide informed consent

Inclusion Criteria: * Adult subjects (aged between 21 and 85 years old) * Subjects can read and speak French * Subjects can perform simple physical exercises * Subjects agreeing to attend the totality of 9 visits * Subjects that have signed the informed consent form Exclusion Criteria: * Clinical staff collaborating with study PI * Subjects with tachycardia (heart rate at rest \> 120bpm) * Subjects with atrial fibrillation * Subjects with diabetes * Subjects with renal dysfunctions * Subjects with hyper-/hypothyroidism * Subjects with pheochromocytoma * Subjects with Raynaud's disease * Subjects with trembling and shivering * Subjects with interarm systolic difference \> 15 mmHg * Subjects with interarm diastolic difference \> 10 mmHg * Subjects with arm paralysis * Women in known pregnancy (for ARM 1 only) * Subjects with an arteriovenous fistula * Subjects with arm amputations * Subjects with the upper arm circumference \< 22cm or \> 42 cm * Subjects with the wrist circumference \> 21 cm * Subjects with the exfoliative skin diseases * Subjects with lymphoedema

Inclusion Criteria: * Age ≥ 18 years * Current or prior diagnosis of breast cancer, ovarian cancer, pancreatic cancer, prostate cancer, colorectal cancer, renal cancer, melanoma, or sarcoma * Ability to understand spoken or written English or Spanish in a healthcare context * Ability to understand and the willingness to sign a written informed consent document * Black or Latinx (qualitative assessment study only) Exclusion Criteria: * Prior cancer genetic testing * Prior germline genetic testing * Active hematologic malignancy (e.g. chronic lymphocytic leukemia) * Currently pregnant * Currently incarcerated

Inclusion Criteria: * 18+ years * diagnosed with open angle glaucoma, who has been or will be implanted with CE-marked MINIject * able to give consent Exclusion Criteria: * eyes with angle closure glaucoma * eyes with traumatic, malignant, uveitic or neovascular glaucoma or discernible congenital anomalies of the anterior chamber angle * patients with known intolerance or hypersensitivity to silicone * patients unable to give consent

Inclusion Criteria: * Patients with primary invasive breast cancer cT1-T3 cN0-2 * Full tumour biology available before initiation of NACT * Oral and written consent * Age ≥ 18 years Exclusion Criteria: * Pregnancy or breast-feeding * Bilateral invasive breast cancer * The presence of musculoskeletal, neurological, respiratory, metabolic or cardiovascular conditions that may prevent safe completion of the exercise demands of the study * Currently performing equal to or more than 150 mins of moderate to high intensity aerobic exercise and 2 sessions per week of moderate intensity resistance exercise

Inclusion Criteria: 1. Individual is diagnosed with hypertension and has a baseline office systolic blood pressure ≥140 mmHg 2. Individual has a baseline office diastolic blood pressure ≥ 90 mmHg 3. Individual has an average systolic baseline home blood pressure ≥135 mmHg Exclusion Criteria: 1. Individual lacks appropriate renal artery anatomy 2. Individual has undergone prior renal denervation 3. Individual has a documented condition that would prohibit or interfere with ability to obtain an accurate blood pressure measurement 4. Individual requires chronic oxygen support or mechanical ventilation other than nocturnal respiratory support for sleep apnea 5. Individual has an estimated glomerular filtration rate (eGFR) of \<45 6. Individual has one or more episode(s) of orthostatic hypotension 7. Individual is pregnant, nursing or planning to become pregnant 8. Individual has primary pulmonary hypertension 9. Individual has documented type 1 diabetes mellitus or poorly-controlled type 2 diabetes mellitus with glycosylated hemoglobin greater than 8.0%

Inclusion Criteria: * Women participating in the mammography screening program. Exclusion Criteria: * None

Inclusion Criteria: * Adults (age 18-75 years at index clinical encounter) * Existing diagnosis of T2DM * BMI ≥35 kg/m2 at index clinical encounter * Have an index clinical encounter with a PCC (family practice or general internal medicine physician, nurse practitioner, or physician assistant) at a randomized study clinic during a 12-month accrual period Exclusion Criteria: * Prior MBS * Patients diagnosed with cancer (except non-melanoma skin cancer), dementia, and/or cirrhosis. * Pregnant or breastfeeding. * In long-term care, palliative care, or hospice care.

Inclusion Criteria: 1. Adolescent (≥12 years of age) and adult patients with a physician's diagnosis of asthma, who are prescribed Atectura inhalation capsule (indacaterol acetate/mometasone furoate; 150/80, 150/160, 150/320 μg) via Breezhaler, as per the approved label information 2. Patients who participate in the study after signing the consent form for data collection and use (Data Privacy ICF) after receiving a clear explanation of the objectives and nature of the study from the investigator (For patients under the age of 18, consent and signature of a legal representative is required) Exclusion Criteria: 1. Patients who are contraindicated for this medicinal product as described in the Precautions for Use in the label information (package insert) A. Patients with hypersensitivity reaction to this medicinal product or any of its constituents B. Because this medicinal product contains lactose, patients with hereditary problems of galactose intolerance, the Lapp lactose deficiency or glucose-galactose malabsorption, etc. 2. Patients with acute asthma symptoms, including acute episodes of bronchospasm, for which a short-acting bronchodilator is required 3. Patients participating in other interventional clinical trials

Inclusion Criteria: * 50-90 years old * Diagnosis (based on a modified SCID-5 Clinical Trials Version to assess DSM-5 diagnoses): Any DSM-5 except: current diagnosis of Psychotic Disorder; diagnosis of Dementia * Recent hospitalization for suicidal ideation or suicide attempt; at hospital admission, Columbia Suicide Severity Rating Scale (CSSR-S) ≥ 2, "Non-specific Active Suicidal Thoughts." * We will also include patients on psychotropics and on after-care community psychotherapy. Exclusion Criteria: * Current diagnosis of Psychotic Disorders; Diagnosis of Dementia * Cognitive Impairment (MMSE ≤ 24) * Acute or severe medical illness (i.e., delirium; decompensated cardiac, liver or kidney failure; major surgery; stroke or myocardial infarction during the three months prior to entry * Aphasia, sensory problems, and/or inability to speak English.

Inclusion Criteria: * Confirmed diagnosis of asthma for at least 6 months * Signed informed consent by parent(s)/legal guardian(s) and assent by the pediatric participant (depending on local requirements) * Participant on stable dose of inhaled low-to-medium dose ICS with one additional controller for at least 4 weeks prior to run-in * Pre-Bronchodilator FEV1 ≥60% to ≤90% of predicted normal at beginning of Run-in and randomization. If FEV1 eligibility criteria are not met at -45min pre-dose of the End of Run-in (Visit 30), the visit can be rescheduled once within 5 days from the previous attempt. * FEV1 reversibility, done using up to 4 puffs of SABA (up to 400μg salbutamol or 360μg albuterol) at Run-in visit (Visit 20): increase \> and/or = 12% (performed according to American Thoracic Society (ATS)/European Respiratory Society (ERS) 2019 guidelines). All participants must perform a reversibility test at start of Run-in. If reversibility is not demonstrated at Run-in, it may be attempted at up to two ad hoc, unscheduled separate visits within 5 days from previous attempt. If reversibility is still not demonstrated after repeated assessment participants must be screen failed * Demonstrated acceptable inhaler use technique for Diskus/Accuhaler (prior to run-in) and Breezhaler (prior to randomization) and able to complete spirometry procedures prior to randomization. * A parent/legal guardian must be designated to complete all e-Diary entries and attend all clinic visits with the participant. * Parents/legal guardian must be willing and able to assist the child with the procedures outlined in the protocol, e.g. compliance with study medication, completion of electronic participant diary * Female participants of child-bearing potential, who might become sexually active, must be informed of the need to prevent pregnancy during the study using effective contraceptive methods. The decision on the contraceptive method should be reviewed at least every 3 months to evaluate the individual need and compatibility of the method chosen. Exclusion Criteria: * Systemic corticosteroid use for any reason within 3 months of Run-in * Participants on low to medium mono ICS alone * Participants requiring six or more puffs of rescue medication per day on more than two consecutive days in the four weeks prior to Screening (Visit 1) and/or in the four weeks prior to the Run-in visit * Participants who have had an asthma attack/exacerbation requiring a) systemic corticosteroids (SCS) or b) hospitalization or c) emergency room visit, within 3 months prior to Screening (Visit 1), or more than 3 separate exacerbations in the 12 months preceding the Screening visit * Participants with a known narrow-angle glaucoma, bladder dysfunction, bladder outlet obstruction or any other conditions where anticholinergic treatment is contraindicated prior to Screening (Visit 1) * Participants with a history of long QT syndrome or whose corrected QT interval (QTc) measured at start of Run-in and confirmed at Baseline (prior to randomization) (Fridericia method) is prolonged (\> 450 msec for boys and girls) and confirmed by a central assessor (these patients should not be rescreened) * Suspected or documented active infections (bacterial, viral, fungal, mycobacterial or other, including active SARS-CoV-2, tuberculosis or atypical mycobacterial disease) of the upper or lower respiratory tract, sinus or middle ear that is not resolved within 6 weeks of Screening (Visit 1) * History of Type I diabetes or uncontrolled Type II diabetes * Participants who are sexually active at screening * Hemoglobin levels outside normal ranges at Run-in (Visit 20) * Female patients of childbearing potential (e.g., are menstruating) who do not agree to abstinence or, if they become sexually active during study participation, do not agree to the use of contraception as defined in the inclusion criteria. Additional protocol-defined inclusion / exclusion criteria may apply.

Inclusion Criteria: * (1) Volunteer to participate and sign informed consent in writing. (2) Past pathological diagnosis of breast cancer followed by radical treatment/surgery for breast cancer, followed by adjuvant chemotherapy followed by radiotherapy. (3) Excluding patients with simple neck lymph node recurrence and patients with distant metastases. (4) There is no secondary malignant tumor in other parts. (5) Age at entry ≥ 18 years old and ≤ 70 years old, both male and female. (6) The Eastern Cooperative Oncology Group (ECOG) has a performance status score of 0 or 1. (7) The expected survival period is ≥2 years. (8) There was no acute radiation lung injury in chest CT examination before and after radiotherapy Exclusion Criteria: * (1) Contraindications to hyperbaric oxygen therapy: lung disease (severe chronic obstructive airway disease, bullous lung disease, acute or chronic lung infection, uncontrolled asthma, untreated pneumothorax), in the past History of ear surgery, middle ear disease (eustachian tube dysfunction, recurrent dizziness), eye disease (retinal detachment). (2) Have received hyperbaric oxygen therapy in the past. (3) Radiation pneumonia had occurred at the time of enrollment or before receiving hyperbaric oxygen therapy. (4) Women who are pregnant or breastfeeding. (5) Patients who have not completed comprehensive breast cancer treatment due to disease progression, intolerable side effects, abandonment of treatment and other reasons. (8) Patients who need mechanical ventilation support. (9) Patients who cannot follow and understand simple commands. (10) Patients with disorientation and mental disorders.

Inclusion Criteria: 1. Age 18 to 75 (inclusive) 2. Diagnosis of type 2 diabetes 3. A1C 7.5% to 12% (inclusive) in the last 2 months. (If A1C is older than 2 months at the baseline visit, a point-of-care or lab A1C may be done for eligibility) 4. Insulin use with or without other classes of glycemia medication use 5. No significant comorbidities that could impair the ability of a primary care team to manage diabetes, including but not limited to end stage renal disease, cognitive impairment, active cancer, and pregnancy 6. Established care within the HealthPartners Care Group, no plans to move within the next year, and willing to participate for the duration of the study 7. Willing and able to follow procedures for collecting blinded CGM data at baseline, 6 and 12 months follow-up 8. Willing to complete surveys at baseline, 3, 6, 9 and 12 months. 9. Willing to use SMBG or CGM, depending on randomization, in the way that their care team recommends and/or how they feel is most useful in managing their diabetes 10. Not currently using personal CGM 11. Not planning to become pregnant Exclusion Criteria: 1. Unwillingness or inability to provide informed consent 2. Deemed not suitable for participation in the study based on any other clinical criteria as determined by study investigator(s)

Inclusion Criteria: * Patients must have biopsy-confirmed metastatic cancer * Be \>= 18 years of age * Be undergoing clinical tumor or circulating tumor deoxyribonucleic acid (DNA) NGS Exclusion Criteria: * Exclude patients who are not English- or Spanish-speaking